RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Learn more about:
Related Clinical Trial
Retrospective Register for Uveal Melanoma Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Adjuvant Melatonin for Uveal Melanoma Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Official Title

A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Brief Summary

      The purpose of this study is to find out what effects, good and/or bad, the drugs everolimus
      and pasireotide have on the patient and on melanoma. Pasireotide is also called SOM-230.
      Pasireotide is an experimental drug and is not approved by the Food and Drug Administration.
      Everolimus is also called RAD001. Everolimus is approved for use in the U.S. for kidney
      cancer. Everolimus is not approved for treatment of melanomas, but early studies show that it
      may help some patients with melanoma.

Study Phase

Phase 2

Study Type


Primary Outcome

Number of Participants With Complete Response (CR)

Secondary Outcome

 Median Progression Free Survival(PFS)


Uveal Melanoma


RAD001 (Everolimus) and Pasireotide (SOM230) LAR

Study Arms / Comparison Groups

 RAD001 and pasireotide LAR
Description:  This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 2010

Completion Date

June 2016

Primary Completion Date

June 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed metastatic uveal

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as >
             or = to 20 mm with conventional techniques or as > or = to 10 mm with spiral CT scan.

          -  Patients may have had any number of prior therapies, but cannot have previously been
             treated with a somatostatin analogue or an mTOR inhibitor. At least 3 weeks must have
             elapsed since the last dose of systemic therapy. At least 6 weeks must have elapsed if
             the last regimen included BCNU or mitomycin C. At least 3 months must have elapsed if
             the last regimen included an anti-CTLA4 antibody. If the last regimen included an
             anti-CTLA4 antibody, radiographic disease progression since this therapy must be

          -  Age > or = to 18 years. Because no dosing or adverse event data are currently
             available on the use of RAD001 and SOM230 in patients <18 years of age, children are
             excluded from this study but will be eligible for future pediatric trials, if

          -  Life expectancy of greater than 3 months.

          -  ECOG performance status 0 or 1.

          -  Patients must have normal organ and marrow function as defined below:

          -  leukocytes > or = to 3,000/mcL

          -  absolute neutrophil count > or = to 1,500/mcL

          -  platelets > or = to 100,000/mcL

          -  hemoglobin > or = to 9.0 g/dL not requiring transfusions within the past 2 weeks

          -  total bilirubin < 1.5 X institutional upper limit of normal

          -  AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal

          -  Creatinine ≤ 1.5 X institutional upper limit of normal or creatinine clearance less
             than 60 ml/min

          -  Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x
             ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only
             be included after initiation of appropriate lipid lowering medication.

          -  INR ≤1.5. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin
             or on a stable dose of LMW heparin for >2 weeks at time of study initiation).

          -  Women of childbearing potential must have a negative serum pregnancy test within 14
             days of the administration of the first study treatment. Women must not be lactating.
             Both men and women of childbearing potential must be advised of the importance of
             using effective birth control measures during the course of the study. Oral,
             implantable, or injectable contraceptives may be affected by cytochrome P450
             interactions, and are therefore not considered effective for this study.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Evidence of disease progression, as determined by the investigator.

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents.

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases. Treated brain
             metastases must have been stable for at least 2 months.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to RAD001 or SOM230.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or bleeding, severely impaired lung function, or psychiatric illness/social
             situations that would limit compliance with study requirements.

          -  Pregnant women are excluded from this study because RAD001 and SOM230 are agents with
             the potential for teratogenic or abortifacient effects. Because there is an unknown
             but potential risk for adverse events in nursing infants, breast-feeding should be

          -  Patients with the presence of active or suspected acute or chronic uncontrolled
             infection or with a history of immunocompromise, including a positive HIV test result
             (ELISA and Western blot). The safety of a potentially immunosuppressive drug like
             everolimus is not proven in patients with HIV. HBV DNA and HCV RNA PCR testing are
             required at screening for all patients with a positive medical history based on risk
             factors and/or confirmation of prior HBV/HCV infection (see Section 8.0 and hepatitis
             B/C risk factor screening form.

          -  Baseline QTc > 450 ms.

          -  Patients with risk factors for torsades de pointes, including uncorrected hypokalemia,
             uncorrected hypomagnesemia, family history of long QT syndrome, clinically
             significant/symptomatic bradycardia, high-grade AV block, autonomic neuropathy
             (including that caused by diabetes or Parkinson's disease, uncontrolled
             hypothyroidism, cirrhosis, or the use of concomitant medications known to prolong the
             QT interval.

          -  Patients with a history of syncope, family history of idiopathic sudden death, a
             history of sustained or clinically significant cardiac arrhythmias, symptomatic
             congestive heart failure (NYHA Class III or IV), unstable angina pectoris, sustained
             ventricular tachycardia, ventricular fibrillation, advanced heart block, or a history
             of acute myocardial infarction within the six months preceding enrollment .

          -  No concomitant anti-cancer chemotherapy or other systemic drugs. Palliative radiation
             therapy will be allowed as long as the patient meets all other eligibility criteria.

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory
             bowel disease), or significant bowel resection that would preclude adequate

          -  Chronic treatment with systemic steroids or another immunosuppressive agent.

          -  Patients should not receive immunization with attenuated live vaccines during study
             period or within 1 week of study entry. Close contact with those who have received
             attenuated live vaccines should be avoided during treatment with RAD001. Examples of
             live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG,
             yellow fever, varicella and TY21a typhoid vaccines.

          -  Patients with prior or concurrent malignancy except for the following: adequately
             treated basal cell or squamous cell skin cancer, or other adequately treated in situ
             cancer, or any other cancer from which the patient has been disease free for five

          -  Patients with a fasting plasma glucose > 1.5 ULN. Note: At the principle
             investigator's discretion, non-eligible patients can be re-screened after adequate
             medical therapy has been instituted.

          -  Patients with symptomatic cholelithiasis.

          -  Patients who have a history of alcohol or drug abuse in the 6 month period prior to
             receiving treatment with pasireotide or RAD001.

          -  History of liver disease, such as cirrhosis or chronic active hepatitis B and C.

          -  Presence of Hepatitis B surface antigen (HbsAg).

          -  Presence of Hepatitis C antibody test (anti-HCV).

          -  History of, or current alcohol misuse/abuse within the past 12 months.

          -  Known gallbladder or bile duct disease, acute or chronic pancreatitis.




18 Years - N/A

Accepts Healthy Volunteers



Michael Postow, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Memorial Sloan Kettering Cancer Center


 Novartis Pharmaceuticals

Study Sponsor

Michael Postow, MD, Principal Investigator, Memorial Sloan Kettering Cancer Center

Verification Date

June 2016